Altered MABA profiles correlate with T2D, obesity and inflammatory bowel disease; experimental data indicate improved glucose homeostasis and reduced adiposity with specific MABAs; potential to modulate gut–brain signaling via GLP-1 and FGF19. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.